Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

PALATINE, Ill., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date), expand the product licenses, and revise the license payment schedule.